William Park, MD
Anesthesiology · Garden Grove, CANPI 1821002288
Payments from drug & device makers
Across 9 payments — averaging $71.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$323
- Medtronic$139
- Saluda Medical Americas, Inc.$107
- SPR Therapeutics, Inc$31
- Redhill Biopharma Inc.$21
- GRT US Holding, Inc.$20
Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$16
What the payments were for
- Food & beverage$642100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 4 | $323 |
| Medtronic | 1 | $139 |
| Saluda Medical Americas, Inc. | 1 | $107 |
| SPR Therapeutics, Inc | 1 | $31 |
| Redhill Biopharma Inc. | 1 | $21 |
| GRT US Holding, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$642 in reported general payments places this provider in the 80th percentile of 5,717 anesthesiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 46 | $16,924 |
| LinzessLinaclotide | 20 | $14,193 |
| OzempicSemaglutide | 12 | $11,168 |
| MyrbetriqMirabegron | 12 | $5,437 |
| Lidocaine | 24 | $3,766 |
| Icosapent Ethyl | 19 | $1,980 |
| Lactated RingersRinger's Solution,lactated | 30 | $1,973 |
| Betamethasone Dipropionate | 11 | $432 |
| Fluocinonide-EFluocinonide/Emollient Base | 12 | $422 |
| Triamcinolone Acetonide | 22 | $306 |
| Niacin ErNiacin | 17 | $206 |
| Rosuvastatin Calcium | 43 | $184 |
| Celecoxib | 20 | $172 |
| Gabapentin | 19 | $155 |
| Mupirocin | 12 | $118 |
Paid to pharmacies, not to this prescriber.
Other anesthesiology in Garden Grove
- Kamal MaheshwariSacramento$1.9M
- Gregory HammerStanford$1.8M
- Neal FlemingSacramento$1.7M
- Joseph AntogniniSacramento$1.4M
- Daniel NguyenDuarte$1.4M
- Jack JengSouth San Francisco$1.3M
- Eilon GabelLos Angeles$1.2M
- Philip BicklerSan Francisco$853K
- Joseph RinehartNewport Beach$824K
- Richard Applegate IiLoma Linda$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.